Discussion

Pediatric Infectious Disease Journal

Volumn 24, Issue 11 SUPPL., 2005, Pages

  Dakhama, Azzeddine ^a   Lee, Young Mok ^a   Gelfand, Erwin W ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN NS1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN; ADRENALIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; PLACEBO; RIBAVIRIN;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; DRUG MECHANISM; GENE; GENETIC TRANSFECTION; HELPER CELL; HUMAN; LOW DRUG DOSE; NONHUMAN; NOTE; NS1 GENE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RNA INTERFERENCE; VIRUS INFECTION; ARTICLE; ASTHMA; BRONCHIOLITIS; CLINICAL TRIAL; DISEASE COURSE; ENVIRONMENTAL FACTOR; INFLAMMATION; LOWER RESPIRATORY TRACT INFECTION; META ANALYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; RESPIRATORY FAILURE; SYSTEMATIC REVIEW; WHEEZING; ABNORMAL RESPIRATORY SOUND; ANIMAL; CHILD; DISEASE MODEL; INFANT; MOUSE; PATHOGENICITY; PRESCHOOL CHILD; REVIEW; VIRAL BRONCHIOLITIS; VIROLOGY;

ANIMALS; ASTHMA; BRONCHIOLITIS, VIRAL; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; HUMANS; INFANT; MICE; RESPIRATORY SOUNDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 33644827026     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000188155.46381.15     Document Type: Article

References (100)

1. Garofalo RP, Haeberle H. Epithelial regulation of innate immunity to respiratory syncytial virus. Am J Respir Cell Mol Biol. 2000;23:581-585.
2. Davies DE. The bronchial epithelium: translating gene and environment interactions in asthma. Curr Opin Allergy Clin Immunol. 2001;1:67-71.
3. Knight DA, Holgate ST. The airway epithelium: structural and functional properties in health and disease. Respirology. 2003;8:432-446.
4. Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J. 2004;23:327-333.
5. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14:778-809.
6. Benedict CA, Norris PS, Ware CF. To kill or be killed: viral evasion of apoptosis. Nat Immunol. 2002;3:1013-1018.
7. Mahr JA, Gooding LR. Immune evasion by adenoviruses. Immunol Rev. 1999;168:121-130.
8. Blair GE, Blair-Zajdel ME. Evasion of the immune system by adenoviruses. Curr Top Microbiol Immunol. 2004;273:3-28.
9. Lybarger L, Wang X, Harris M, Hansen TH. Viral immune evasion molecules attack the ER peptide-loading complex and exploit ER-associated degradation pathways. Curr Opin Immunol. 2005;17:71-78.
10. LeVine AM, Whitsett JA. Pulmonary collectins and innate host defense of the lung. Microbes Infect. 2001;3:161-166.
11. Taube C, Dakhama A, Gelfand EW. Insights into the pathogenesis of asthma utilizing murine models. Int Arch Allergy Immunol. 2004;135:173-186.
12. Ginsberg HS, Moldawer LL, Sehgal PB, et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA. 1991;88:1651-1655.
13. Kajon AE, Gigliotti AP, Harrod KS. Acute inflammatory response and remodeling of airway epithelium after subspecies B1 human adenovirus infection of the mouse lower respiratory tract. J Med Virol. 2003;71:233-244.
14. + T cells in primary and secondary influenza pneumonia. Immunity. 1998;8:683-691.
15. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. J Med Virol. 1988;26:153-162.
16. Openshaw PJ. Immunity and immunopathology to respiratory syncytial virus. The mouse model. Am J Respir Crit Care Med. 1995;152(4, pt 2):S59-62.
17. Alvarez R, Harrod KS, Shieh WJ, Zaki S, Tripp RA. Human metapneumovirus persists in BALB/c mice despite the presence of neutralizing antibodies. J Virol. 2004;78:14003-14011.
18. Walter MJ, Morton JD, Kajiwara N, Agapov E, Holtzman MJ. Viral induction of a chronic asthma phenotype and genetic segregation from the acute response. J Clin Invest. 2002;110:165-175.
19. Bonville CA, Easton AJ, Rosenberg HF, Domachowske JB. Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents. J Virol. 2003;77:1237-1244.
20. Cook PM, Eglin RP, Easton AJ. Pathogenesis of pneumovirus infections in mice: detection of pneumonia virus of mice and human respiratory syncytial virus mRNA in lungs of infected mice by in situ hybridization. J Gen Virol. 1998;79(Pt 10):2411-2417.
21. Schwarze J, Hamelmann E, Bradley KL, Takeda K, Gelfand EW. Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest. 1997;100:226-233.
22. Wells MA, Albrecht P, Ennis FA. Recovery from a viral respiratory infection. I. Influenza pneumonia in normal and T-deficient mice. J Immunol. 1981;126:1036-1041.
23. Schwarze J, O'Donnell DR, Rohwedder A, Openshaw PJ. Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med. 2004;169:801-805.
24. Gelfand EW. Pro: mice are a good model of human airway disease. Am J Respir Crit Care Med. 2002;166:5-6; discussion 7-8.
25. Bates JH, Irvin CG. Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol. 2003;94:1297-1306.
26. Folkerts G, Busse WW, Nijkamp FP, Sorkness R, Gem JE. Virus-induced airway hyperresponsiveness and asthma. Am J Respir Crit Care Med. 1998;157(6 pt 1):1708-1720.
27. Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201:937-947.
28. Thurlbeck WM. Pathology of chronic airflow obstruction. Chest. 1990;97:6S-10S.
29. Goldie RG, Pedersen KE. Mechanisms of increased airway microvascular permeability: role in airway inflammation and obstruction. Clin Exp Pharmacol Physiol. 1995;22:387-396.
30. Pare PD, Roberts CR, Bai TR, et al. The functional consequences of airway remodeling in asthma. Monaldi Arch Chest Dis. 1997;52:589-596.
31. Jacoby DB. Virus-induced asthma attacks. JAMA. 2002;287:755-761.
32. Fryer AD, el-Fakahany EE, Jacoby DB. Parainfluenza virus type 1 reduces the affinity of agonists for muscarinic receptors in guinea-pig lung and heart. Eur J Pharmacol. 1990;181:51-58.
33. Larsen GL, Colasurdo GN. Neural control mechanisms within airways: disruption by respiratory syncytial virus. J Pediatr. 1999;135(2 pt 2):21-27.
34. Tripp RA, Moore D, Winter J, Anderson LJ. Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice. J Virol. 2000;74:1614-1622.
35. Tripp RA, Barskey A, Goss L, Anderson LJ. Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection. J Neuroimmunol. 2002;129:141-153.
36. King KA, Hu C, Rodriguez MM, Romaguera R, Jiang X, Piedimonte G. Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am J Respir Cell Mol Biol. 2001;24:101-107.
37. Auais A, Adkins B, Napchan G, Piedimonte G. Immunomodulatory effects of sensory nerves during respiratory syncytial virus infection in rats. Am J Physiol Lung Cell Mol Physiol. 2003;285:L105-L113.
38. Dakhama A, Park JW, Taube C, et al. Alteration of airway neuropeptide expression and development of airway hyperresponsiveness following respiratory syncytial virus infection. Am J Physiol Lung Cell Mol Physiol. 2005;288:L761-L770.
39. Dakhama A, Larsen GL, Gelfand EW. Calcitonin gene-related peptide: role in airway homeostasis. Curr Opin Pharmacol. 2004;4:215-220.
40. Jafri HS, Chavez-Bueno S, Mejias A, et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis. 2004;189:1856-1865.
41. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest. 1991;88:1026-1033.
42. Culley FJ, Pollott J, Openshaw PJ. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med. 2002;196:1381-1386.
43. Gelfand EW, Joetham A, Cui ZH, et al. Induction and maintenance of airway responsiveness to allergen challenge are determined at the age of initial sensitization. J Immunol. 2004;173:1298-1306.
44. Dakhama A, Park JW, Taube C, et al. The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production. J Immunol. 2005;175:1876-1883.
45. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998;282:2258-2261.
46. Kuperman DA, Huang X, Koth LL, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med. 2002;8:885-889.
47. Walter DM, McIntire JJ, Berry G, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol. 2001;167:4668-4675.
48. Taube C, Duez C, Cui ZH, et al. The role of IL-13 in established allergic airway disease. J Immunol. 2002;169:6482-6489.
49. Park JW, Taube C, Yang ES, et al. Respiratory syncytial virus-induced airway hyperresponsiveness is independent of IL-13 compared with that induced by allergen. J Allergy Clin Immunol. 2003;112:1078-1087.
50. Welliver RC, Kaul TN, Ogra PL. The appearance of cell-bound IgE in respiratory-tract epithelium after respiratory-syncytial-virus infection. N Engl J Med. 1980;303:1198-1202.
51. Dakhama A, Park JW, Taube C, et al. The role of virus-specific immunoglobulin E in airway hyperresponsiveness. Am J Respir Crit Care Med. 2004;170:952-959.
52. Frick OL, German DF, Mills J. Development of allergy in children. I. Association with virus infections. J Allergy Clin Immunol. 1979;63:228-241.
53. Busse WW. The relationship between viral infections and onset of allergic diseases and asthma. Clin Exp Allergy. 1989;19:1-9.
54. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171:137-141.
55. Korppi M, Piippo-Savolainen E, Korhonen K, Remes S. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol. 2004;38:155-160.
56. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541-545.
57. Herz U, Lacy P, Renz H, Erb K. The influence of infections on the development and severity of allergic disorders. Curr Opin Immunol. 2000;12:632-640.
58. Schwarze J, Gelfand EW. Respiratory viral infections as promoters of allergic sensitization and asthma in animal models. Eur Respir J. 2002;19:341-349.
59. O'Donnell DR, Openshaw PJ. Anaphylactic sensitization to aeroantigen during respiratory virus infection. Clin Exp Allergy. 1998;28:1501-1508.
60. Stephens R, Randolph DA, Huang G, et al. Antigen-nonspecific recruitment of Th2 cells to the lung as a mechanism for viral infection-induced allergic asthma. J Immunol. 2002;169:5458-5467.
61. John AE, Berlin AA, Lukacs NW. Respiratory syncytial virus-induced CCL5/RANTES contributes to exacerbation of allergic airway inflammation. Eur J Immunol. 2003;33:1677-1685.
62. Makela MJ, Tripp R, Dakhama A, et al. Prior airway exposure to allergen increases virus-induced airway hyperresponsiveness. J Allergy Clin Immunol. 2003;112:861-869.
63. Schwarze J, Makela M, Cieslewicz G, et al. Transfer of the enhancing effect of respiratory syncytial virus infection on subsequent allergic airway sensitization by T lymphocytes. J Immunol. 1999;163:5729-5734.
64. Matsuse H, Behera AK, Kumar M, Rabb H, Lockey RF, Mohapatra SS. Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness. J Immunol. 2000;164:6583-6592.
65. Peebles RS Jr., Hashimoto K, Collins RD, et al. Immune interaction between respiratory syncytial virus infection and allergen sensitization critically depends on timing of challenges. J Infect Dis. 2001;184:1374-1379.
66. Barends M, Van Oosten M, De Rond CG, et al. Timing of infection and prior immunization with respiratory syncytial virus (RSV) in RSV-enhanced allergic inflammation. J Infect Dis. 2004;189:1866-1872.
67. Lemanske RF Jr. Viruses and asthma: inception, exacerbation, and possible prevention. J Pediatr. 2003;142:S3-S7; discussion S7-S8.
68. Hall CB. Respiratory syncytial virus: a continuing culprit and conundrum. J Pediatr. 1999;135(2 pt 2):2-7.
69. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr. 2003;143(suppl 5):112-117.
70. Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am J Respir Crit Care Med. 2001;163(3 pt 2):S2-S6.
71. Wennergren G, Kristjansson S. Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases. Eur Respir J. 2001;18:1044-1058.
72. Openshaw PJ, Dean GS, Culley FJ. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatr Infect Dis J. 2003;22(Suppl 2):S58-S64; discussion S64-S65.
73. Stein RT, Martinez FD. Asthma phenotypes in childhood: lessons from an epidemiological approach. Paediatr Respir Rev. 2004;5:155-161.
74. Kalina WV, Gershwin LJ. Progress in defining the role of RSV in allergy and asthma: from clinical observations to animal models. Clin Dev Immunol. 2004;11:113-119.
75. Maggon K, Barik S. New drugs and treatment for respiratory syncytial virus. Rev Med Virol. 2004;14:149-168.
76. Chavasse RJ, Bastian-Lee Y, Seddon P. How do we treat wheezing infants? Evidence or anecdote. Arch Dis Child. 2002;87:546-547.
77. Flores G, Horwitz RI. Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis. Pediatrics. 1997;100(2 pt 1):233-239.
78. King VJ, Viswanathan M, Bordley WC, et al. Pharmacologic treatment of bronchiolitis in infants and children: a systematic review. Arch Pediatr Adolesc Med. 2004;158:127-137.
79. Patel NR, Hammer J, Nichani S, Numa A, Newth CJ. Effect of inhaled nitric oxide on respiratory mechanics in ventilated infants with RSV bronchiolitis. Intensive Care Med. 1999;25:81-87.
80. Tibby SM, Hatherill M, Wright SM, Wilson P, Postle AD, Murdoch IA. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2000;162 (4 pt 1):1251-1256.
81. Luchetti M, Ferrero F, Gallini C, et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr Crit Care Med. 2002;3:261-268.
82. Martinon-Torres F, Rodriguez-Nunez A, Martinon-Sanchez JM. Heliox therapy in infants with acute bronchiolitis. Pediatrics. 2002;109:68-73.
83. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov. 2004;3:831-844.
84. Cade A, Brownlee KG, Conway SP, et al. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch Dis Child. 2000;82:126-130.
85. Doull IJ, Lampe FC, Smith S, Schreiber J, Freezer NJ, Holgate ST. Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial. BMJ. 1997;315:858-862.
86. Garrison MM, Christakis DA, Harvey E, Cummings P, Davis RL. Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics. 2000;105:E44.
87. van Woensel JB, Kimpen JL, Sprikkelman AB, Ouwehand A, van Aalderen WM. Long-term effects of prednisolone in the acute phase of bronchiolitis caused by respiratory syncytial virus. Pediatr Pulmonol. 2000;30:92-96.
88. Wong JY, Moon S, Beardsmore C, O'Callaghan C, Simpson H. No objective benefit from steroids inhaled via a spacer in infants recovering from bronchiolitis. Eur Respir J. 2000;15:388-394.
89. Smith DW, Frankel LR, Mathers LH, Tang AT, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med. 1991;325:24-29.
90. Guerguerian AM, Gauthier M, Lebel MH, Farrell CA, Lacroix J. Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial. Am J Respir Crit Care Med. 1999;160:829-834.
91. Long CE, Voter KZ, Barker WH, Hall CB. Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo. Pediatr Infect Dis J. 1997;16:1023-1028.
92. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med. 2005;11:50-55.
93. Zhang W, Yang H, Kong X, et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med. 2005;11:56-62.
94. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization, I: a field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969;89:435-448.
95. Graham BS. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Am J Respir Crit Care Med. 1995;152(4 pt 2):S63-S66.
96. Welliver RC. Respiratory syncytial virus infection: therapy and prevention. Paediatr Respir Rev. 2004;5(suppl A):S127-S133.
97. Meissner HC, Long SS. American Academy of Pediatrics Committee on Infectious Disease and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6 pt 1):1447-1452.
98. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 1993;329:1524-1530.
99. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93-99.
100. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3 pt 1):531-537.